The FDA has started a priority review of MSD's Keytruda as neoadjuvant and adjuvant treatment of locally advanced head and neck squamous cell carcinoma (HNSCC), with a decision due by 23rd June.

June 1, 2025 • NPR's Ayesha Rascoe plays the puzzle with listener Clive Jerram of Rockville, Md., and Weekend Edition Puzzlemaster Will Shortz.